What is Oncodesign Precision Medicine?
Oncodesign Precision Medicine, established in 1995 and based in Dijon, France, is a biopharmaceutical entity dedicated to the research and development of advanced therapeutic and diagnostic tools. The company offers comprehensive drug discovery services, encompassing in vitro and in vivo pharmacology, metabolism studies, and pharmacokinetics analysis for drug candidates. Furthermore, Oncodesign provides translational biomarker services, biodecontamination, biosafety, and biobanking capabilities. Its core focus lies in advancing kinase inhibitor development programs targeting oncology, central nervous system disorders, and inflammatory conditions. The company actively engages in strategic partnerships to propel oncology treatments and collaborates on the development of fibrosis drug candidates, positioning itself as a key player in precision medicine through scientific expertise and technological innovation.
How much funding has Oncodesign Precision Medicine raised?
Oncodesign Precision Medicine has raised a total of $6.3M across 1 funding round:
Other Financing Round
$6.3M
Other Financing Round (2023): $6.3M with participation from Crédit Agricole, Societe Generale, and Caisse d'Epargne
Key Investors in Oncodesign Precision Medicine
Crédit Agricole
Credit Agricole is a leading French banking and financial services group providing a full spectrum of financial services including French retail banking, international retail banking, specialized financial services, asset management, insurance, private banking, and corporate and investment banking.
Societe Generale
Société Générale S.A. is a French-based multinational financial services company offering French Retail, Private Banking and Insurance. The company was founded in 1864 and is based in Paris, Ile-de-France, France.
Caisse d'Epargne
Founded in 1818 and headhquartered in Paris, France, Caisse d'Epargne is a semi-cooperative bank that focuses on retail and private banking.
What's next for Oncodesign Precision Medicine?
The recent major strategic investment in Oncodesign Precision Medicine signals a pivotal stage for the company, likely enabling accelerated development of its oncology and fibrosis drug candidates. This capital will support the expansion of its integrated drug discovery and translational biomarker services, potentially leading to new strategic partnerships and advancements in precision medicine. The company's focus on kinase inhibitors and its comprehensive service offerings suggest a trajectory towards scaling its operations and clinical trial advancements.
See full Oncodesign Precision Medicine company page
